
The results of an investigation into how we might better tailor therapy for ovarian cancer have been released. The goal of the study was to investigate the role of the hormone HE4 in modulating an ovarian cancer’s response to hormones and hormonal therapies. HE4 is a biomarker that is elevated in ovarian cancer and is known to play a role in resistance to chemotherapy.
http://feeds.sciencedaily.com/~r/sciencedaily/~3/F8e-QULOHUo/140917121227.htm